Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma

Saved in:
Bibliographic Details
Published in:Journal of the American Academy of Dermatology 2002-12, Vol.47 (6), p.956-961
Main Authors: Shapiro, Michael, Rook, Alain H., Lehrer, Michael S., Junkins-Hopkins, Jacqueline M., French, Lars E., Vittorio, Carmela C.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Biopsy, Needle
Combined Modality Therapy
Dermatology
Follow-Up Studies
Humans
Immunohistochemistry
Immunologic Factors - therapeutic use
Lymphoma, T-Cell, Cutaneous - pathology
Lymphoma, T-Cell, Cutaneous - therapy
Male
Medical sciences
Middle Aged
Neoplasm Staging
Skin involvement in other diseases. Miscellaneous. General aspects
Skin Neoplasms - pathology
Skin Neoplasms - therapy
Tetrahydronaphthalenes - therapeutic use
Treatment Outcome
Ultraviolet Therapy - methods
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0190-9622
1097-6787
DOI:10.1067/mjd.2002.124816